These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

711 related items for PubMed ID: 19243834

  • 1. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration.
    Kaiser PK, Registry of Visudyne AMD Therapy Writing Committee, Boyer DS, Garcia R, Hao Y, Hughes MS, Jabbour NM, Kaiser PK, Mieler W, Slakter JS, Samuel M, Tolentino MJ, Roth D, Sheidow T, Strong HA.
    Ophthalmology; 2009 Apr; 116(4):747-55, 755.e1. PubMed ID: 19243834
    [Abstract] [Full Text] [Related]

  • 2. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration.
    Lazic R, Gabric N.
    Ophthalmology; 2007 Jun; 114(6):1179-85. PubMed ID: 17544776
    [Abstract] [Full Text] [Related]

  • 3. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration.
    Dhalla MS, Shah GK, Blinder KJ, Ryan EH, Mittra RA, Tewari A.
    Retina; 2006 Jun; 26(9):988-93. PubMed ID: 17151484
    [Abstract] [Full Text] [Related]

  • 4. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study).
    Costa RA, Jorge R, Calucci D, Melo LA, Cardillo JA, Scott IU.
    Graefes Arch Clin Exp Ophthalmol; 2007 Sep; 245(9):1273-80. PubMed ID: 17333238
    [Abstract] [Full Text] [Related]

  • 5. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.
    Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, ANCHOR Study Group.
    Ophthalmology; 2009 Jan; 116(1):57-65.e5. PubMed ID: 19118696
    [Abstract] [Full Text] [Related]

  • 6. Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration.
    Bakri SJ, Couch SM, McCannel CA, Edwards AO.
    Retina; 2009 May; 29(5):573-8. PubMed ID: 19430278
    [Abstract] [Full Text] [Related]

  • 7. Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration.
    Smith BT, Dhalla MS, Shah GK, Blinder KJ, Ryan EH, Mittra RA.
    Retina; 2008 May; 28(5):675-81. PubMed ID: 18463509
    [Abstract] [Full Text] [Related]

  • 8. Analysis of outcomes for intravitreal bevacizumab in the treatment of choroidal neovascularization secondary to ocular histoplasmosis.
    Cionni DA, Lewis SA, Petersen MR, Foster RE, Riemann CD, Sisk RA, Hutchins RK, Miller DM.
    Ophthalmology; 2012 Feb; 119(2):327-32. PubMed ID: 22133795
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results.
    Larsen M, Schmidt-Erfurth U, Lanzetta P, Wolf S, Simader C, Tokaji E, Pilz S, Weisberger A, MONT BLANC Study Group.
    Ophthalmology; 2012 May; 119(5):992-1000. PubMed ID: 22424834
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone.
    Augustin AJ, Puls S, Offermann I.
    Retina; 2007 Feb; 27(2):133-40. PubMed ID: 17290193
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration.
    Ladewig MS, Karl SE, Hamelmann V, Helb HM, Scholl HP, Holz FG, Eter N.
    Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):17-25. PubMed ID: 17701197
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Triple therapy for neovascular age-related macular degeneration (verteporfin photodynamic therapy, intravitreal dexamethasone, and intravitreal bevacizumab).
    Ehmann D, García R.
    Can J Ophthalmol; 2010 Feb; 45(1):36-40. PubMed ID: 20130708
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.